CX 901
Alternative Names: CX-901Latest Information Update: 14 Dec 2022
At a glance
- Originator Cartexell
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies
Most Recent Events
- 13 Dec 2022 GI cell biotechnologies entered into a research license and option agreement with Optieum biotechnologies
- 22 Sep 2022 Early research in Haematological malignancies in South Korea (Parenteral) (Cartexell pipeline, September 2022)
- 28 Apr 2022 Cartexell collaborates with GICELL and Helixmith to develop cell therapy products